<DOC>
	<DOCNO>NCT00565760</DOCNO>
	<brief_summary>This Phase 3 double-blind , multiple dose safety extension study Q8003 administer daily dos 36 mg morphine/24 mg oxycodone ( Q8003 36mg/24mg ) treatment period 4 week . Patients acute moderate severe pain complete participation one designate QRxPharma , Inc. acute pain lead-in study eligible trial .</brief_summary>
	<brief_title>Extension Study Evaluate Safety Q8003 Patients With Acute Moderate Severe Pain</brief_title>
	<detailed_description>The currently designate acute pain lead-in study Study Q8003-007 , safety efficacy study Q8003 management post-bunionectomy pain .</detailed_description>
	<criteria>Patient complete participation one designate eligible QRxPharma , Inc. acute pain leadin study . Patient BMI ≤35 . Patient anticipate take first dose study medication Extension Study longer 24 hour take final dose study medication leadin study . Patient good health determine Investigator via physical examination Extension Study Baseline Visit . If female , patient least one year postmenopausal ( define one year without menses ) , surgically sterile ( must document ) , practice effective contraception , opinion Investigator , willing continue use effective contraception duration participation study . If female , patient nonlactating , childbearing potential , negative urine pregnancy test result Baseline Visit . Patient pulseoximetry measurement ≥95 % , respiration rate ≥12 breaths/minute , systolic blood pressure ≥100 mm Hg , diastolic blood pressure ≥50 mm Hg Extension Study Baseline Visit . Patient willing refrain drive throughout duration participation study . Patient acute asthma , head injury , elevate intracranial pressure , convulsive state , congestive heart failure ( NYHA classification III IV ) , current cardiac arrhythmia , current transient cerebral ischemic attack , current uncontrolled unstable coexistent systemic disease , serious intercurrent illness , medical condition , laboratory abnormality , extenuate circumstance , opinion Investigator , would preclude participation study . Patient allergy , hypersensitivity , contraindication opioids . Patient poorly control hypertension ( systolic blood pressure &gt; 180 mm Hg diastolic blood pressure &gt; 95 mm Hg despite antihypertensive medication ) Extension Study Baseline Visit . Patient currently take tramadol anticipates take tramadol course study . Patient currently take antipsychotic drug , monoamine oxidase inhibitor , muscle relaxant , medication treatment depression . Patient currently take opioid analgesic Q8003 opioid study medication , anticipate take opioid analgesic Q8003 opioid study medication course study . Patient high risk addiction : patient history substance abuse ( exclude nicotine caffeine ) , family history substance abuse , history adverse consequence relate substance abuse include legal issue . Patient history drug alcohol use dependence , opinion Investigator , would interfere adherence study requirement . Patient medical , psychological , cognitive , social and/or legal condition could , opinion Investigator , compromise patient safety interfere ability patient give inform consent and/or comply study requirement , include necessary time commitment . Patient receive investigational medication within 30 day prior first dose study drug study Q8003 schedule receive investigational drug Q8003 course study . Patient previously admit study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acute</keyword>
	<keyword>Pain</keyword>
</DOC>